
|Articles|August 1, 2006
Melanoma drug 'fast-tracked'
West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.
Advertisement
West Haven, Conn. - The kidney cancer drug Nexavar has been granted fast track designation by the Food and Drug Administration for treatment of advanced melanoma, manufacturer Bayer Pharmaceuticals announced.
Nexavar was approved last year for treatment of renal cell carcinoma.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Rethinking Pathogenesis and Severity Assessment in Chronic Hand Eczema
5


















